share_log

Why Are Histogen Shares Trading Higher Today?

Why Are Histogen Shares Trading Higher Today?

为什么 Histogen 股票今天的交易价格走高？
Benzinga ·  2023/03/17 10:24
  • The U.S. Patent and Trademark Office (USPTO) has issued US Patent providing broad coverage for Histogen Inc's (NASDAQ:HSTO) portfolio of anti-inflammatory caspase inhibitors, including CTS-2090.
  • This patent includes information that CTS-2090 has demonstrated potent oral activity in a well-characterized model of ulcerative colitis.
  • CTS-2090 provided statistically significant protection against inflammation-driven damage to the lining of the GI tract and protected against weight loss.
  • While CTS-2090 is a potent inflammatory, it had no effect in well-accepted cellular and in vivo models of apoptosis, confirming its high selectivity as an anti-inflammatory caspase inhibitor, the company said.
  • "We are pleased that this important patent has issued. It builds upon Histogen's growing proprietary caspase inhibitor portfolio that includes the U.S. patent No. 11,447,497 issued in September of 2022. This previously issued patent discloses a broad class of novel pan-caspase inhibitors with unique chemical properties," stated Alfred Spada, EVP and Chief Scientific Officer of Histogen.
  • Price Action: HSTO shares are up 59% at $1.37 on the last check Friday.
  • 美国专利商标局（USPTO）已颁发美国专利，为以下方面提供了广泛的覆盖范围 Histogen Inc （纳斯达克股票代码：HSTO）抗炎半胱氨酸蛋白酶抑制剂产品组合，包括 CTS-2090。
  • 该专利包括以下信息：CTS-2090 在一种典型的溃疡性结肠炎模型中显示出有效的口服活性。
  • CTS-2090 提供了具有统计学意义的保护作用，可防止炎症引起的胃肠道内膜损伤，并可防止体重减轻。
  • 该公司表示，尽管 CTS-2090 是一种强效的炎性炎症，但它对广为接受的细胞和体内细胞凋亡模型没有影响，这证实了其作为抗炎半胱氨酸蛋白酶抑制剂的高选择性。
  • “我们很高兴这项重要专利的颁发。它建立在Histogen不断增长的专有半胱氨酸蛋白酶抑制剂产品组合的基础上，其中包括2022年9月发布的第11,447,497号美国专利。这项先前发布的专利揭示了一大类具有独特化学特性的新型泛半胱氨酸蛋白酶抑制剂。” Histogen执行副总裁兼首席科学官阿尔弗雷德·斯帕达说。
  • 价格走势： 在周五的最后一张支票中，HSTO股价上涨了59％，至1.37美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发